You are here

Motegrity Approved for Treatment of Chronic Idiopathic Constipation

Drug Expected to Launch in 2019, Offering Hope to 35 Million U.S. Adults

The FDA has approved Motegrity (prucalopride, Shire), a once-daily, oral treatment for adults with chronic idiopathic constipation (CIC).

Prucalopride, a selective serotonin-4 (5-HT4) receptor agonist, works by enhancing the natural movements of the colon muscle–known as peristalsis–providing a different option to other prescription CIC treatments.

In double-blind, placebo-controlled, randomized, multicenter clinical studies lasting 12 weeks, more patients taking prucalopride achieved the primary endpoint than those in the placebo group (19–38% for prucalopride ≤2 mg vs. 10–20% with placebo) across five of the six trials. Although cardiovascular safety was an issue with other 5-HT4 agonists, prucalopride’s trial data indicated no increase in cardiovascular events. However, suicidal ideation and attempts were reported.

Prucalopride is contraindicated in patients with inflammatory bowel disorders, perforations, or structural disorders of the gut wall.

The most common adverse reactions are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence and fatigue.

Sources: MedpageToday.com, Drugs.com, December 17, 2018.

More Headlines

iPSC Therapy Designed to Salvage Eye, Prevent Vision Loss
Health Outcomes Have No Improvement
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
Targeted Antibody for FGR3-Positive Mutation
Method Could Lead to Manufacturing Corneas for Transplants
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Potential Life-Saving Device Can be Implanted in 2-LB Babies
New Therapy for Patients With HCC Who Previously Received Nexavar
Aggressive Disease Represents Around 6% of All New Cases of NHL